Emerging targeted therapies for melanoma treatment (Review)

被引：38

作者：

Russo, Angela ^{[1
]}

Ficili, Bartolomea ^{[1
]}

Candido, Saverio ^{[1
]}

Pezzino, Franca Maria ^{[1
]}

Guarneri, Claudio ^{[2
]}

Biondi, Antonio ^{[3
]}

Travali, Salvatore ^{[1
]}

McCubrey, James A. ^{[4
]}

Spandidos, Demetrios A. ^{[5
]}

Libra, Massimo ^{[1
]}

机构：

[1] Univ Catania, Dept Biomed Sci, Sect Gen Pathol & Oncol, Lab Translat Oncol & Funct Genom, I-95124 Catania, Italy

[2] Univ Messina, Dept Social Territorial Med, Dermatol Sect, I-98125 Messina, Italy

[3] Univ Catania, Dept Surg, I-95124 Catania, Italy

[4] E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC USA

[5] Univ Crete, Sch Med, Dept Virol, Iraklion 71003, Crete, Greece

来源：

INTERNATIONAL JOURNAL OF ONCOLOGY | 2014年 / 45卷 / 02期

关键词：

melanoma; MAPK/AKT pathway; targeted therapies; IMMUNOSTIMULATORY MONOCLONAL-ANTIBODIES; OVERCOME ACQUIRED-RESISTANCE; PHASE-II TRIAL; B-RAF; METASTATIC MELANOMA; CLINICAL DEVELOPMENT; PIK3CA MUTATIONS; BRAF INHIBITORS; OPEN-LABEL; IN-VITRO;

D O I：

10.3892/ijo.2014.2481

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cutaneous melanoma is an aggressive cancer with a poor prognosis for patients with advanced disease. The identification of several key molecular pathways implicated in the pathogenesis of melanoma has led to the development of novel therapies for this devastating disease. In melanoma, both the Ras/Raf/MEK/ERK (MAPK) and the PI3K/AKT (AKT) signalling pathways are constitutively activated through multiple mechanisms. Targeting various effectors of these pathways with pharmacologic inhibitors may inhibit melanoma cell growth and angiogenesis. Ongoing clinical trials provide hope to improve progression-free survival of patients with advanced melanoma. This review summarizes the most relevant studies focused on the specific action of these new molecular targeted agents. Mechanisms of resistance to therapy are also discussed.

引用

页码：516 / 524

页数：9

共 50 条

[1] Emerging targeted therapies for melanoma
Johnson, Douglas B.
Pollack, Megan H.
Sosman, Jeffrey A.
EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (02) : 195 - 207
[2] Treatment of acral and mucosal melanoma: Current and emerging targeted therapies
Zhang, Jiaran
Tian, Huichun
Mao, Lili
Si, Lu
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 193
[3] Emerging Therapies in the Treatment of Advanced Melanoma
Massand, Sameer
Neves, Rogerio I.
CLINICS IN PLASTIC SURGERY, 2021, 48 (04) : 713 - 733
[4] Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma
Christiansen, Shelly A.
Khan, Shaheer
Gibney, Geoffrey T.
CANCER JOURNAL, 2017, 23 (01): : 59 - 62
[5] Novel Targeted Therapies for the Treatment of Metastatic Melanoma
Kudchadkar, Ragini
OCHSNER JOURNAL, 2010, 10 (02): : 117 - 124
[6] Melanoma: Molecular pathogenesis and emerging target therapies (Review)
Russo, Alessia E.
Torrisi, Elena
Bevelacqua, Ylenia
Perrotta, Rosario
Libra, Massimo
McCubrey, James A.
Spandidos, Demetrios A.
Stivala, Franca
Malaponte, Grazia
INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 34 (06) : 1481 - 1489
[7] Melanoma brain metastasis: overview of current management and emerging targeted therapies
Fonkem, Ekokobe
Uhlmann, Erik J.
Floyd, Scott R.
Mahadevan, Anand
Kasper, Ekkehard
Eton, Omar
Wong, Eric T.
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (10) : 1207 - 1215
[8] Targeted Therapies in Melanoma
Moschos, Stergios J.
Pinnamaneni, Ramya
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 24 (02) : 347 - +
[9] Targeted therapies in melanoma
Queirolo, Paola
Acquati, Mirko
CANCER TREATMENT REVIEWS, 2006, 32 (07) : 524 - 531
[10] Targeted therapies for melanoma
Leiter, U.
Meier, F.
Garbe, C.
HAUTARZT, 2014, 65 (07): : 600 - 606

← 1 2 3 4 5 →